Affini-T Therapeutics is developing T-cell receptor (TCR)-based immunotherapies targeting solid tumors associated with oncogenic mutations such as TP53 R175H and KRAS G12D/G12V. The company aims to enhance the precision of cancer treatment by utilizing specific T-cell therapies to improve patient outcomes in oncology.
Funding
$317.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LBFounders
Product
Problem
Solid tumors with oncogenic mutations like TP53 R175H and KRAS G12D/G12V are difficult to treat with existing therapies, leading to poor patient outcomes. Current cancer treatments often lack the precision needed to target tumor cells specifically, resulting in off-target effects and limited efficacy.
Solution
Affini-T Therapeutics is developing T-cell receptor (TCR)-based immunotherapies designed to target solid tumors with specific oncogenic mutations. Their approach enhances the precision of cancer treatment by engineering T-cells to recognize and eliminate tumor cells expressing mutated proteins such as TP53 R175H, KRAS G12D, and KRAS G12V. By targeting these specific mutations, Affini-T aims to improve patient outcomes in oncology while minimizing damage to healthy tissues. The company utilizes two complementary therapeutic modalities to deliver targeted T-cell therapies directly to the tumor microenvironment.
Target Audience
The primary target audience includes patients with solid tumors harboring oncogenic mutations such as TP53 R175H and KRAS G12D/G12V, as well as oncologists and medical professionals seeking more precise and effective cancer treatments.
Features
- TCR-based immunotherapies targeting specific oncogenic mutations (e.g., TP53 R175H, KRAS G12D/G12V)
- Engineered T-cells designed to recognize and eliminate tumor cells expressing mutated proteins
- Two complementary therapeutic modalities for targeted delivery of T-cell therapies